ArticleCancer diagnosis & prognosis
Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Protein tyrosine phosphatase kappa (PTPRK), a recognized tumor suppressor, has been implicated in cancer progression of certain solid tumors. This study investigated the role of PTPRK in the progression of pancreatic cancer. Materials and Methods: PTPRK transcripts were determined in a pancreatic cancer cohort using real-time PCR. The functional impact of PTPRK was evaluated in pancreatic cancer cells with PTPRK knockdown, followed by an assessment of its implications in disease progression. Results: Elevated PTPRK expression was observed in pancreatic cancer and was positively correlated with tumor T stage. Knockdown of PTPRK led to reduced cellular proliferation and decreased expression of cyclin-dependent kinase 6 (CDK6). Additionally, an increase in VEGFC expression was noted in PTPRK knockdown cells. Conclusion: Up-regulation of PTPRK in pancreatic cancer is associated with disease progression and poor prognosis. PTPRK facilitates cancer cell proliferation through CDK6, highlighting the potential for therapeutic strategies targeting PTPRK and CDK6 in pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.